Early-phase oncology trials are among the most demanding studies in clinical research. Patient journeys are longer, dosing regimens evolve, disease types multiply, and protocols change—often more than once. Every delay has consequences, not just operationally, but for the patients waiting on these treatments.
Technology has become essential to managing that complexity. At Suvoda, oncology represents over 40% of the trials we support, and more than half of those are early-phase. Sponsors are increasingly recognizing that the right technology, deployed early, pays dividends throughout the life of a study. But not all technology is built for this environment. Suvoda RTSM, the next evolution of Suvoda IRT, is designed from the ground up for the flexibility that early-phase oncology demands.
The common thread running through early-phase oncology is change. Protocols evolve. Interim analyses shift dosing strategies. Cohorts expand or restructure. Suvoda RTSM doesn’t just accommodate change—it’s designed for it.
Advanced cohort management lets study teams create new cohorts, assign dose levels, set visit schedules, and configure patient limits by disease indication and treatment regimen, without programming changes. When circumstances shift, teams can respond immediately.
Basket studies require managing multiple disease or tumor types simultaneously. Disease type management in Suvoda RTSM lets teams add or remove types in real time, with the same flexibility they have in cohort management.
Early-phase studies rarely have complete dosing information at protocol approval. Dose and dispensation management lets teams configure dose interruptions, add new doses, and specify dispensation quantities mid-study—with confidence that Suvoda RTSM is applying the right logic throughout
Comparator and adjuvant therapy management gives teams control over sourcing strategies at the site or country level and the ability to shift between local and central sourcing as needs change. Integrated predictive resupply reduces drug waste and keeps supply aligned to patient demand.
Dynamic visit scheduling and cycle expansion lets teams automate cycle expansion and update patient visit schedules directly—no programming required. Configurable rules across all cycles and visits give teams the control they need even when study duration is uncertain.
Getting a clinical trial from contract to go-live has always been one of the most persistent drags on timelines, and one of the hardest to compress. For early-phase oncology, where startup delays directly delay patient access to investigational treatments, this is where Suvoda RTSM can make another meaningful difference.
Suvoda’s agentic RTSM uses AI agents to accelerate distinct parts of the study build—including configuration, customization, and testing—taking a study from project kickoff to User Acceptance Testing in as little as two weeks. That’s a reduction of up to 80% in startup timelines. The same agentic approach applies to change orders, so protocol amendments don’t have to derail momentum.
Beyond startup speed, Suvoda’s AI assistant Sofia supports monitoring the RTSM system for potential issues, surfaces alerts, and delivers intelligent insights that give study teams clearer visibility into trial status. For teams managing complex, fast-moving early-phase studies, that means less time hunting for information and more time acting on it.
Suvoda RTSM is the operational backbone of an early-phase oncology trial—but it doesn’t work in isolation. Recruitment and retention are persistent challenges in early-phase studies, and the patient experience across the full trial journey has a direct impact on both.
The Suvoda Platform extends beyond RTSM / IRT to address the clinical and logistical touchpoints that determine whether patients can participate and stay enrolled. Suvoda eCOA captures patient-reported outcomes and clinician assessments digitally, reducing burden for patients managing serious illness and improving data quality for study teams. Greenphire Patient Payments streamlines reimbursement so patients aren’t waiting on compensation that affects their ability to continue. Greenphire Travel removes the logistical friction of getting to and from sites. And eConsent simplifies the informed consent process.
When these tools operate on the same platform as Suvoda RTSM, the result is a unified view of the patient — dosing status, outcomes data, payments, and visit schedule all synchronized in real time. For early-phase oncology, where keeping the right patients enrolled through shifting protocols is a critical success factor, that connected picture is what makes confident decision making possible.
Suvoda RTSM does more than accommodate the complexity of early-phase oncology; it gives study teams the control to move through it decisively. Change is inevitable. Protocol amendments happen. Interim analyses redirect studies. Cohorts evolve.
What shouldn’t be inevitable is delay. With Suvoda RTSM—built for flexibility, accelerated by agentic AI, and connected to a broader patient-centric technology ecosystem—teams can adapt without losing momentum. That keeps novel treatments on track, and keeps the patients who need them in reach.
Rob Hummel
Chief Operating Officer
Suvoda